Bio-Gene Technology Ltd (ASX: BGT) - Share Price
- Current share price for BGT : $0.017
Bio-Gene Technology Ltd (BGT) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance. Its products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across crop protection, grain storage, public health and consumer uses.
BGT General Information +
| ASX Code | BGT |
| Website | N/A |
| Industry/Sector | Fertilizers & Agricultural Chemicals |
| Market Cap ($M) | 7 |
| BGT Share Price | $0.017 |
| Day High | $0.017 |
| Day Low | $0.017 |
| Last Close | $0.017 |
| BGT Share Price Movement | - ( No change ) |
Prices as at 16:40, 4 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Bio-Gene Technology Ltd (BGT) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Bio-Gene Technology Ltd (BGT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Bio-Gene Technology Ltd (BGT) price-sensitive announcements
BGT - Quarterly Activities/Appendix 4C Cash Flow Report
Bio-Gene Technology Limited, an Australian agtech company, reported its quarterly activiti
Bio-Gene Technology Ltd (BGT)
31 Jul 2026 | 11:25 AM
31 Jul 2026 | 11:25 AM
BGT - Results of Placement
Bio-Gene Technology Ltd has announced a successful capital raising of $3.21 million throug
Bio-Gene Technology Ltd (BGT)
26 May 2026 | 9:59 AM
26 May 2026 | 9:59 AM
BGT - Trading Halt
On 22 May 2026, Bio-Gene Technology Limited (ASX: BGT) requested a trading halt for its se
Bio-Gene Technology Ltd (BGT)
22 May 2026 | 9:28 AM
22 May 2026 | 9:28 AM
BGT - Quarterly Activities/Appendix 4C Cash Flow Report
Bio-Gene Technology Limited reported on its activities for the quarter ending March 31, 20
Bio-Gene Technology Ltd (BGT)
27 Apr 2026 | 11:55 AM
27 Apr 2026 | 11:55 AM
Bio-Gene Technology Ltd (BGT) Recent ASX Announcements
BGT Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$2.33 | -$0.80 | -38.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$2.58 | -$1.20 | -6.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$2.41 | -$1.30 | -29.70% | 0.00 | 0.00 | 0.00% | 0.0% |
BGT Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Bio-Gene Technology Ltd (BGT) | $7M | -0.3852 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Nufarm Limited (NUF) | $1,253M | 1.6328 | -0.2518 | 1.1579 | 26.7432 | 35.7456 | 16.5650 | 0.00% | 0.00% | 1.81% |
BGT Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Peter May | Research & Development, Executive Director | 29 May 2015 |
| Mr Owen Timothy Grogan | Chief Executive Officer, Managing Director | 28 Aug 2023 |
| Mr Andrew Wallace Guthrie | Non-Executive Director | 26 Apr 2021 |
| Mr Christopher Mark Ramsey | Non-Executive Director | 12 May 2023 |
| Mr Alex Huong Soo Ding | Non-Executive Director, Non-Executive Chairman | 12 May 2023 |
Bio-Gene Technology Ltd (BGT) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 10 Aug 2026 | GUTHRIE, Andrew | Issued | Indirect Shares | 200,000 | $0.025 | $5,000.000 |
| 10 Aug 2026 | GROGAN, Owen | Issued | Indirect Shares | 200,000 | $0.025 | $5,000.000 |
| 10 Aug 2026 | RAMSEY, Christopher | Issued | Indirect Shares | 200,000 | $0.025 | $5,000.000 |
See all changes in directors' interest & trades for Bio-Gene Technology Ltd (BGT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
BGT Management
| Name | Position |
|---|---|
| Drew Speedy | Chief Financial Officer,Company Secretary |
| Peter May | Executive Director - Research and Development |
BGT Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Bio-Gene Technology Ltd (BGT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 34,001,034 (11.10%) | Vana Belle Pty Ltd |
| 32,791,245 (10.70%) | Dr Choon Huat Lee |
| 21,109,174 (6.90%) | Mark Chang |
| 18,995,859 (6.20%) | Alina Barlow |
| 15,166,491 (5%) | Citicorp Nominees Pty Ltd |
BGT Calendar of Events
| Date | Event |
|---|---|
| 27 August 2027 | Report (Annual) |
| 27 August 2027 | Report (Prelim) |
| 23 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
